Clinical Trials on Charcot-Marie-Tooth Disease Type 2R in Switzerland

Total 4 results

Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Austria, Switzerland
University Hospital Freiburg
Charite University, Berlin, Germany; Icahn School of Medicine at Mount Sinai; Ohio State University and other collaborators

Recruiting

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy (SENIOR)

Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer

United States, Cyprus, Germany, Switzerland
European Organisation for Research and Treatment...

Recruiting

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma (Best Of)

Oropharyngeal Cancer | Hypopharyngeal Squamous Cell Carcinoma | Supraglottic Squamous Cell Carcinoma

Spain, Belgium, Switzerland, Italy, United Kingdom, Germany, France, Poland
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain

3

Subscribe